On the Effects of Serotonin Reuptake Inhibitors in Major Depression by Hieronymus, Fredrik
Göteborg, 2019 
SAHLGRENSKA AKADEMIN 
On the Effects of Serotonin Reuptake Inhibitors in Major Depression 
Akademisk avhandling 
som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs 
universitet kommer att offentligen försvaras i Hörsal Arvid Carlsson, Medicinaregatan 3, 
fredagen den 15 februari, klockan 13:00 
av Fredrik Hieronymus 
Fakultetsopponent: Prof. Stuart Montgomery,  
Imperial College London, United Kingdom 
 
Avhandlingen baseras på följande delarbeten 
I. Fredrik Hieronymus, Johan F. Emilsson, Staffan Nilsson, Elias Eriksson. Consistent 
superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed 
mood in patients with major depression. Mol. Psychiatry 2016;21:523-530. 
II. Fredrik Hieronymus, Staffan Nilsson, Elias Eriksson. A mega-analysis of fixed-dose 
trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of 
three selective serotonin reuptake inhibitors. Transl. Psychiatry. 2016;6:e834. 
III. Fredrik Hieronymus, Alexander Lisinski, Staffan Nilsson, Elias Eriksson. Efficacy of 
selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of 
citalopram and paroxetine in adult depression. Mol. Psychiatry. 2018;23:1731-1736. 
IV. Jakob Näslund, Fredrik Hieronymus, Alexander Lisinski, Staffan Nilsson, Elias 
Eriksson. Effects of selective serotonin reuptake inhibitors on rating-scale-assessed 
suicidality in adults with depression. Br. J. Psychiatry 2018;212:148-154. 
V. Fredrik Hieronymus, Alexander Lisinski, Staffan Nilsson, Elias Eriksson. Impact of 
baseline severity on the effects of selective serotonin reuptake inhibitors in depression: an 
item-based patient-level post hoc analysis. Submitted. 
VI. Alexander Lisinski, Fredrik Hieronymus, Jakob Näslund, Staffan Nilsson, Elias 
Eriksson. Item-based analysis of the effects of duloxetine in depression: a patient-level 
post hoc study. Submitted. 
 
 
INSTITUTIONEN FÖR NEUROVETENSKAP  
OCH FYSIOLOGI 
Göteborg, 2019 
ISBN: 978-91-7833-312-7 (TRYCK)  
ISBN: 978-91-7833-313-4 (PDF) 
http://hdl.handle.net/2077/58234 
 
On the Effects of Serotonin Reuptake Inhibitors in Major Depression 
Fredrik Hieronymus 
Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska 
Academy at the University of Gothenburg, Gothenburg, Sweden 
Abstract 
This thesis focuses on the antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) and how 
these are reflected by the Hamilton Depression Rating Scale (HDRS). To this end, we have assembled a 
large data set of placebo-controlled SSRI trials in major depression, and used this for a series of post-hoc 
patient-level analyses. 
   Thus, in a population of 8 262 patients treated with either of four SSRIs (citalopram, fluoxetine, 
paroxetine, or sertraline) or placebo, we have assessed (1) to what extent the various symptoms included in 
the HDRS separate between active treatment and placebo, and contrasted this to the sum-score of all HDRS 
items, which has been the conventional effect parameter, (2) whether the effects of SSRIs are dose-
dependent, (3) whether side effects are necessary for SSRIs to outperform placebo, (4) if SSRIs increase or 
decrease suicidal ideation, and (5) whether only patients with high baseline depression severity respond to 
treatment with SSRIs.  
   We found that the influence of drug treatment on individual HDRS items differs vastly with regard to both 
the size and direction of effect. While depressed mood and other core symptoms of depression are 
consistently improved by SSRI treatment, HDRS items that may reflect typical SSRI side effects, such as 
e.g., gastrointestinal symptoms and sexual symptoms, respond, on average, negatively. The HDRS sum-
score thus represents an aggregate of beneficial effects on core depression symptoms and detrimental effects 
on possible side-effect related items. Further, we suggest that the balance between these domains vary with 
time under treatment, with side-effects being relatively more influential early in treatment, thereby 
obfuscating significant positive effects otherwise evident as early as after one week of treatment.  
   We also found evidence for a dose-response relationship, i.e., very low SSRI doses were more effective 
than placebo, but less effective than higher doses; this relation plateaued at the low to mid-range of currently 
recommended doses. We did not find any evidence in support of the hypothesis that side effects be an 
indispensable prerequisite for antidepressant efficacy, or that side effect severity moderates response. We 
could replicate previous studies showing SSRIs to decrease suicidal ideation in subjects ≥ 25 years of age, 
but could not detect a significant influence of SSRIs in either direction in young adults (18 ≤ age < 25). We 
found baseline symptom severity to be positively associated with SSRI efficacy when measured by the 
HDRS sum-score. This was however not the case for core depression symptoms where instead patients 
improved equally regardless of baseline severity. We suggest this to be partly due to non-core symptoms 
being absent in low-severity patients, thus leaving less room for improvement and more room for worsening 
on side-effect related items. Most of these observations were replicated in a population of 3575 patients 
from studies of the serotonin and noradrenaline reuptake inhibitor duloxetine.  
   We conclude i) that the sum-score of the HDRS rating scale is an insufficient and insensitive measure of 
antidepressant efficacy, ii) that the use of this outcome parameter has led to an underestimation of the true 
efficacy of SSRIs and SNRIs, particularly at the early phase of treatment and in subjects with relatively mild 
depression, iii) that normal doses of antidepressants are superior to low doses but not inferior to high doses, 
iv) that antidepressant effects are not, as has been suggested, secondary to side effects breaking the blind, 
and v) that the net effect of antidepressants on suicidality is beneficial, at least in subjects ≥ 25 years of age. 
In conjunction, the results rebut many of the claims that have been put forward by those questioning the 
usefulness of antidepressants. 
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